GeoPharma, Inc.

Roche Holding has offered to buy the rest of Genentech, about a 44% stake it doesn't already own, for $89 a share, or about $43.7 billion.

The deal would mark one of the Swiss drug maker's biggest acquisitions and would mean about $750 million to $850 million in pre-tax savings.

I decided to give you a feature about a very solid pharmaceutical company, and why they are primed for continued growth. I always love a company that is willing to put their profits back into research for continued product growth and share price growth. A great company with a great chart.

EntreMed Inc. (Nasdaq: ENMD) is a pharmaceutical company focused on the development of therapeutic pharmaceutical candidates to treat cancer and inflammation. To reach its goals, the company must maintain an experienced and aggressive management team. EntreMed today announced Thomas H. Bliss will serve as the company’s senior vice president of corporate and business development.

Demographic trends and the persistence of medical afflictions should continue to drive revenue growth for healthcare providers, and the non-discretionary nature of their products limits volatility. This article examines some of the sub-industries within healthcare and their potential to provide good investments.